Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, L. Green, Elizabeth Lieschke et al.|Nature Communications|2018Cited by 299
Prognostic gene expression signature for high-grade serous ovarian cancerJoshua Millstein, Scott D. Brown, Timothy Budden et al.|Annals of Oncology|2020Cited by 173
Chore or priority? Barriers and facilitators affecting dilator use after pelvic radiotherapy for gynaecological cancerCarissa Bonner, Ilona Juraskova, K. Nattress et al.|Supportive Care in Cancer|2011Cited by 40
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nešić, Harold C. Sullivan, John J. Krais et al.|Molecular Cancer|2024Cited by 28